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Abstract
Dietary fat consumption during accelerated stages of mammary gland development, 
such as peripubertal maturation or pregnancy, is known to increase the risk for breast 
cancer. However, the underlying molecular mechanisms are not fully understood. 
Here we examined the gene expression profile of mouse mammary epithelial cells 
(MMECs) on exposure to a high-fat diet (HFD) or control diet (CD). Trp53−/− female 
mice were fed with the experimental diets for 5 weeks during the peripubertal period 
(3-8 weeks of age). The treatment showed no significant difference in body weight 
between the HFD-fed mice and CD-fed mice. However, gene set enrichment anal-
ysis predicted a significant enrichment of c-Myc target genes in animals fed HFD. 
Furthermore, we detected enhanced activity and stabilization of c-Myc protein in 
MMECs exposed to a HFD. This was accompanied by augmented c-Myc phosphoryl-
ation at S62 with a concomitant increase in ERK phosphorylation. Moreover, MMECs 
derived from HFD-fed Trp53−/− mouse showed increased colony- and sphere-forming 
potential that was dependent on c-Myc. Further, oleic acid, a major fatty acid con-
stituent of the HFD, and TAK-875, an agonist to G protein-coupled receptor 40 (a re-
ceptor for oleic acid), enhanced c-Myc stabilization and MMEC proliferation. Overall, 
our data indicate that HFD influences MMECs by stabilizing an oncoprotein, pointing 
to a novel mechanism underlying dietary fat-mediated mammary carcinogenesis.
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1  | INTRODUC TION
Various biological and epidemiological studies have reported that di-
etary fat consumption is one of the major risk factors that increases 
the prevalence of breast cancer.1-6 The majority of health hazards 
related to excessive fat intake are associated with being overweight 
or obese. However, additional evidence in nonobese mouse models 
has indicated that HFD alone, and not the associated obesity, is re-
sponsible for mammary carcinogenesis. The proliferation of MMECs 
is known to be stimulated by high fat intake independent of body 
weight.7-10 Furthermore, HFD induces inflammatory cytokines and 
growth factors, which ultimately cause mammary tumors in non-
obesogenic mice.7,11 Additionally, the incidence of premenopausal 
mammary tumor is higher among red meat-consuming healthy-
weight individuals than overweight individuals. Hence, these pre-
vious findings propose that excessive fat consumption directly 
facilitates mammary carcinogenesis.
Exposure to HFD during the peripubertal stage (3-8 weeks of 
age) in mice has been shown to increase the risk of developing mam-
mary tumors in later life, suggesting sustaining an irreversible effect 
of high fat intake.7-9 Moreover, such exposure to a HFD is sufficient 
to promote murine MMEC proliferation and enhance the recruit-
ment of eosinophils and mast cells.7 Excessive intake of dietary fat 
during this pubertal transition period has been shown to decrease 
event-free survival time in a 7,12-dimethylbenzanthracene-induced 
mouse mammary tumor model.8 Similarly, BALB/c mice carrying xe-
nografted Trp53-null mammary gland have been reported to develop 
spindle cell carcinoma more frequently, which resembles the human 
claudin-low type breast cancer upon high-fat feeding.9
P53 is a tumor suppressor that engages in diverse cellular pro-
cesses including cell cycle regulation, DNA repair machinery, senes-
cence, and apoptosis. Specifically, TP53 mutations manifest in 30% of 
human breast carcinomas and more than 80% of triple-negative breast 
cancers.12 Trp53−/− mice are susceptible to a range of tumors including 
lymphomas, which frequently develop at 6 months of age.13 Hence, 
mammary tumors rarely appear during the short lifespan of Trp53−/− 
unless additional factors are involved. Thus, in most of the studies, 
mammary carcinogenesis with Trp53-null status is investigated using 
alternative approaches. One such common method is to transplant 
Trp53−/− mammary epithelium into a host mouse.9 However, this pro-
cedure has been suggested to disrupt the innate interaction between 
mammary epithelium and surrounding host tissue.14
In the present study, we fed Trp53−/− mice with HFD or CD during 
the peripubertal stage and cultured MMECs for a defined period to 
analyze the gene expression profile. Furthermore, we determined 
differentially expressed genes between the MMECs derived from 
HFD-fed and CD-fed mice to identify molecules that potentially link 
HFD to mammary carcinogenesis. Gene set enrichment analysis of 
microarray data predicted that c-Myc oncoprotein-targeted genes 
were significantly enriched in the MMECs from HFD-fed mice com-
pared to those detected in CD-fed mice. Furthermore, our findings 
suggest that HFD elevates c-Myc stability and protein levels through 
alteration in its phosphorylation status. Based on these findings, 
we propose a potential mechanism whereby irrespective of obe-
sity, excessive fat intake during puberty contributes to mammary 
tumorigenesis.
2  | MATERIAL S AND METHODS
2.1 | Mice and diets
The Trp53−/− mice15 were obtained from RIKEN BRC (#CDB0001K), 
interbred, and maintained in a cohort. Wild-type C57BL/6 mice 
were purchased from SLC (Shizuoka, Japan) at 3 weeks of age. 
Trp53−/− female mice were randomly assigned to a specific diet, CD 
or HFD. They were fed from 3 weeks of age to 8 weeks of age. The 
HFD (D12492, 60% kcal fat) and CD (D12450B, 10% kcal fat) were 
purchased from Research Diets (Table S1). The HFD was replaced 
every 2 days as this diet is susceptible to oxidation. Littermates were 
equally distributed between groups. Mice were housed in poly-
sulfone cages and received food and water ad libitum. They were 
maintained under aseptic conditions and exposed to a 12:12 hour 
light : dark cycle with a relative humidity of 45%-50% at 20-
24°C. Mouse experiments were undertaken in accordance with a 
Kanazawa University Institutional Animal Care and Use Committee-
approved protocol (AP-153426).
2.2 | Genotyping of mice
Mouse genomic DNA was isolated from the cut tails of the mouse 
after digestion in a buffer containing 0.1 mol/L Tris-HCl (pH 8.0), 
5 mmol/L EDTA, 0.25 mol/L NaCl, 0.2% SDS, and 100 mg/mL pro-
teinase K at 55°C. Polymerase chain reaction was carried out to 
identify the genotype according to a method published previously.16
2.3 | Mouse mammary epithelial cell 
isolation and culture
Mouse mammary glands were isolated from 8-week-old female 
Trp-53−/− mice that had been fed with HFD or CD for 5 weeks. The 
mammary tissue was dissociated with 1 mL collagenase/hyaluro-
nidase (#07912; STEMCELL Technologies) and 9 mL DMEM/F-12 
(048-29785; Wako) supplemented with 5% FBS (#SH30079; 
HyClone) for 6 hours at 37°C with occasional pipetting and vor-
texing. To make the dissociation process fast, tissue was minced 
beforehand. The resultant material was further dissociated to ob-
tain the single-cell suspension using 0.25% trypsin-EDTA (3 min-
utes) at 37°C, followed by 5 mg/mL Dispase (Life Technologies) 
and 1 mg/mL DNase I (1 min) (Sigma-Aldrich). The cell suspension 
was filtered through 40 µm mesh (#352340; Falcon). The MMECs 
were enriched in the sample by removing unwanted cells such as 
hematopoietic, endothelial, and fibroblastic cells (CD45+, TER119+, 
CD31+, and BP-1+) using EasySep Mouse Epithelial Cell Enrichment 
2338  |     KULATHUNGA eT AL.
kit (#19758; STEMCELL Technologies) and Purple EasySep magnet 
(18 000; STEMCELL Technologies) following the manufacturer’s 
instructions. Enriched MMECs were cultured on 0.1% (w/v) gela-
tin-coated (Iwaki) dishes in FBS-free Complete EpiCult-B Medium 
(Mouse) (#05610; STEMCELL Technologies) supplemented with 
10 ng/mL rh bFGF (PeproTech), 10 ng/mL rh EGF (PeproTech), 
4 µg/mL (0.0004%) heparin (#07980; STEMCELL Technologies), 
and 5 µg/mL insulin (Sigma-Aldrich).17-19
2.4 | MCF10A cell culture
MCF10A cells were cultured in Mammary Epithelial Growth Media 
(CC-3150; Lonza) supplemented with 0.1 µg/mL cholera toxin solu-
tion (Wako).
2.5 | Microarray analysis
Total RNA was extracted from MMECs with the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. Cyanine-
3-labeled cRNA was prepared from 0.2 µg RNA using the Low 
Input Quick Amp Labeling Kit (Agilent Technologies) according 
to the manufacturer’s instructions, followed by RNAeasy column 
purification (Qiagen). Dye incorporation and cRNA yield were 
checked with the NanoDrop ND-1000 Spectrophotometer. The 
microarray analysis was carried out with Whole Mouse Genome 
microarray 4 × 44K version 2.0 (G2519F #26655; Agilent). The flu-
orescence intensity was measured with Agilent DNA Microarray 
Scanner (G2539A). Data were normalized and filtered with 3 fil-
ters using GeneSpring software 12.1 (Agilent). In brief, raw data 
were normalized with their 75 percentile values. These microarray 
data were deposited in the Gene Expression Omnibus database 
(GSE144328). The normalized microarray results were analyzed by 
the weighted average difference method.20 Enrichment analysis 
by EnrichR (version 2.1) was undertaken by R.21,22 Gene set en-
richment analysis (A) was carried out on signal to noise metrics 
using gene sets obtained from H hallmark gene sets and C2 cu-
rated gene sets, which are freely available at http://www.broad 
insti tute.org/gsea/index.jsp.23
2.6 | Reverse transcription-qPCR
Reverse transcription-qPCR was carried out on total RNA isolated 
from cultured MMECs using TRIzol (#15596018; Life Technologies) 
according to the manufacturer’s protocol. Isolated RNA was re-
verse-transcribed at 37°C with random primers to obtain cDNA, 
and the qPCR analysis was done as described previously.24,25 
TaqMan primers used in the qPCR were c-Myc (Mm00487803_
m1), Mycn (Mm00627179_m1), Mycl1 (Mm00493155_m1), 
Cdkn1a (Mm04205640_g1), Klk8 (Mm00501179_m1), and Actb 
(Mm00607939_s1).
2.7 | Antibodies and IB
Mouse mammary epithelial cell were lysed by RIPA buffer with 
protease inhibitor cocktail (25 955; Nacalai Tesque) and the 
whole-cell lysate was obtained for IB analysis. Enhanced chemilu-
minescence reagent (WBKLS0500; Millipore, MA01821) was used 
to obtain the signals and visualize bands using the ImageQuant 
LAS4000 chemiluminescent image system. Quantification of 
the band intensity was undertaken using ImageJ-NIH software 
(https://imagej.nih.gov/ij/). c-Myc (9402), P-c-Myc-(S62) (E1J4K) 
(13 748), p44/42 MAPK (9102), P-p44/42 MAPK (T202/Y204), 
GSK-3β (D5C5Z) XP(R) (12 456), P-GSK-3β (S9) (D85E12) (5558) 
XP(R), P-Rb(S807/811) (9308), cyclin D1 (2926), PCNA (D3H8P) 
XP(R) (13 110), anti-mouse IgG HRP-linked (7076), and anti-rabbit 
IgG HRP-linked (7074) Abs were purchased from Cell Signaling 
Technology. Anti-Myc (phospho-Thr58) (Y011034), anti-A-tubulin 
mouse MAB (DM1A) and Rb (C-15) sc:50 Abs were purchased 
from Applied Biological Materials, EMD Millipore, and Santa Cruz 
Biotechnology, respectively.
2.8 | Protein half-life assay
Primary MMECs were treated with 10 µg/mL CHX (C7698; Sigma-
Aldrich), and whole-cell lysate was collected at 0, 10, 25, 45, and 
60 minutes and immunoblotted with the Ab to c-Myc.
2.9 | Colony formation assay
Mouse mammary epithelial cells were dissociated and resultant sin-
gle cells were plated at 4000 cells/well in a 60-mm dish. Colonies 
were stained with modified Giemsa solution after 14 days of in-
cubation, and the positive area for staining was quantified using 
ImageJ-NIH software. The experiment was repeated using different 
mouse pairs (experiment and control groups) at different passage 
numbers of cells.
2.10 | Mammosphere assay
Cells in monolayer culture were dissociated, filtered through 
40-µm cell strainer to obtain single-cell suspension, and seeded 
at a density of 2500 cells/well onto a 96-well ultralow adherence 
plate (EZ-BindShut II; AGC Techno Glass) containing 1% methyl-
cellulose containing αMEM medium supplemented with B27 
(Life Technologies), 20 ng/mL rh EGF (Wako), and 20 ng/mL rh 
bFGF (Wako). After 14 days of incubation, mammospheres were 
visualized under an inverted phase-contrast microscope, and BZ 
software was used to analyze on BZ-9000 (Keyence) equipped 
with a hybrid cell counting module. The experiment was repeated 
using MMECs obtained from different mouse pairs including 
littermates.
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2.11 | Fatty acid treatments
Mouse mammary epithelial cells were cultured in FBS-free complete 
EpiCult-B medium (Mouse) (#05610; STEMCELL Technologies) as de-
scribed above and treated with 3 mmol/L BSA-conjugated OA (stock 
solution; #O3008) (Sigma-Aldrich) or 30% w/v fatty acid-free BSA 
(015-23871; Wako) alone for 48 hours. For the PA treatment, BSA-
conjugated PA 3 mmol/L stock solution was prepared according to a 
protocol described previously using sodium palmitate (P9767; Sigma-
Aldrich) and BSA (A7030; Sigma-Aldrich) and treated for 48 hours.26
2.12 | Serum fatty acid analysis
Nonesterified fatty acids present in serum were quantified using a 
LabAssay NEFA kit (Wako) using the manufacturer’s protocol.
2.13 | G protein-coupled receptor 40 stimulation
Mouse mammary epithelial cells were cultured in FBS-free complete 
EpiCult-B medium (Mouse) (#05610; STEMCELL Technologies) as 
described above and treated with 100 nmol/L GPR40 agonist (TAK-
875; ChemScene) or DMSO (Nacalai Tesque).
2.14 | Immunohistochemistry
Immunohistochemical analysis was carried out on 4-µm specimens 
obtained from paraffin-embedded mammary glands. Tissue slides 
were stained with the Ab to PCNA ([D3H8P] XP[R] [13 110]; Cell 
Signaling Technology) using a DAB+ Substrate Chromogen detection 
system (Dako) and counter-stained with hematoxylin.
2.15 | Inhibitor treatment
Mouse mammary epithelial cells were treated with a Myc inhibitor, 
10058-F4, 5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone 




Student’s t test and 2-way ANOVA tests were used for the statistical 
analysis. P values less than 0.05 were considered as statistically sig-
nificant. GraphPad Prism 8.0 (GraphPad Software) and basic statistic 
tools available in Microsoft Excel were used in statistical analysis. 
*P < .05, **P < .01, ***P < .001, and ****P < .0001.
3  | RESULTS
3.1 | High-fat diet promotes MMEC proliferation 
before inducing obesity
To identify the genes that could be responsible for mammary car-
cinogenesis stimulated by peripubertal high fat intake, we fed 
Trp53−/− mice with HFD or CD for 5 weeks from the age of 3 weeks 
(Figure 1A). Diet composition is shown in Table S1. The HFD and 
CD contain equal calories. The HFD-fed mice showed no signifi-
cant difference in gain of body weight over the experimental period 
compared to CD-fed mice (Figure 1B). We collected mammary gland 
tissues from these mice (Figure 1C), isolated MMECs according to 
previously published methods,17-19 and cultured them under 2-D con-
ditions (Figure 1D). During culture, MMECs derived from HFD-fed 
F I G U R E  1   Establishment of mouse 
mammary epithelial cells (MMECs). A, 
Schema of feeding of Trp53-null mice 
with a high-fat diet (HFD) or a control 
diet (CD) for 5 wk. Mice were killed 
at 8 wk and mammary glands were 
harvested. B, Body weight of the mice 
at the time of death (N = 7 for each 
group). C, Ventral view of abdominal 
(bottom) and thoracic (upper) mammary 
glands incised from either side of the 
mouse. D, MMECs cultured in serum-free 
EpiCult-B medium supplemented with 
recombinant human (rh) basic fibroblast 
growth factor, rh epidermal growth factor, 
heparin, and insulin. Images captured 
24 h (left) and 72 h (right) after seeding. 
Scale bar = 200 µm. Data are mean ± SE. 
*P < .05 (Student’s t test) n.s., non-
significant
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mice (HFD-MMECs) were observed to proliferate significantly faster 
than MMECs derived from CD-fed mice (CD-MMECs) (Figure 2A). In 
addition, we found that HFD-MMECs were more efficient in form-
ing colonies (Figure 2B,C) and mammospheres (Figure 2D,E) than 
those in CD-MMECs. We detected an elevated expression of p-Rb 
and cyclin D1 in HFD (Figure 2F). Moreover, an increased PCNA ex-
pression was detected in MMECs and the mammary gland using IB 
and immunohistochemistry analysis, respectively, in HFD-fed mice 
(Figure 2G). Thus, our results indicate that HFD promotes the prolif-
eration of MMECs before mice gain obesity.
3.2 | High-fat diet alters expression of c-Myc 
target genes
To investigate the molecular basis underlying the phenotypic 
changes in HFD-MMECs, we analyzed the gene expression profile 
of HFD-MMECs (N = 3) and CD-MMECs (N = 3) using microarray 
analysis. Principal component analyses emphasized a significant 
difference between the gene expression of HFD-MMECs and CD-
MMECs (Figure 3A). Moreover, an unbiased gene cluster analysis 
of top-ranked upregulated or downregulated genes revealed that 
MMECs acquired distinct gene expression patterns following HFD 
exposure (N = 3) (Figure 3B and Table S2). We analyzed the top 100 
genes upregulated in HFD-MMECs compared to CD-MMECs using 
Enrichr software and identified that networks related to “pathways 
in cancer” were enriched (Figure 3C and Table S3). Gene set enrich-
ment analysis exhibited predefined gene sets related to cell cycle 
progression, cell proliferation (Figure S1A and Table S4), and c-Myc 
target genes among upregulated genes in HFD (Figures 3D and S1B, 
Table S5).
Next, we determined the relative mRNA expression of c-Myc 
transcriptional targets Klk8 (a positive target) and Cdkn1a (a negative 
target) using RT-qPCR. Results were found to be consistent with the 
microarray analysis (Figure 3E). Subsequently, we speculated that the 
altered expression of c-Myc target genes was due to aberrant c-Myc 
expression at the transcriptional or translational stage. Although we 
did not observe a distinct expression in the MYC proto-oncogene 
F I G U R E  2   High-fat diet (HFD) 
stimulates growth of mouse mammary 
epithelial cells (MMECs). A, WST-1-based 
cell proliferation assay of MMECs derived 
from mice fed control diet (CD-MMECs; 
N = 3) or HFD (HFD-MMECs; N = 3) 
B, Colony formation assay of MMECs 
derived from mice fed with CD or HFD. C, 
Quantitative analysis of the colony area 
(N = 3 for each group). D, Mammosphere 
formation assay of CD-MMECs and 
HFD-MMECs. Scale bar = 100 µm. E, 
Quantitative analysis of the sphere area 
(N = 3 for each group). F, Immunoblotting 
(IB) of indicated proteins in HFD-MMECs 
and CD-MMECs. Experiments were 
done in triplicate or duplicate. α-Tubulin 
was used as a loading control. G, IB of 
proliferating cell nuclear antigen (PCNA) 
in CD-MMECs and HFD-MMECs (upper), 
a representative immunohistochemistry 
staining of PCNA in the mammary gland 
tissue in mice fed CD or HFD (bottom). 
Scale bar = 100 µm. Data are mean ± SE. 
*P < .05, **P < .01 (Student’s t test). p-, 
phosphorylated; Rb, retinoblastoma 
protein
     |  2341KULATHUNGA eT AL.
2342  |     KULATHUNGA eT AL.
family genes, c-Myc (Figure 3F), Mycn, and Mycl (Figure S2), IB analysis 
detected a robust induction of c-Myc expression in HFD (Figure 3G).
Furthermore, we ascertained whether the increased expression 
of c-Myc target genes in the microarray analysis and subsequent 
RT-qPCR is dependent on elevated c-Myc protein levels detected in 
HFD. Here, we treated MMECs with a well-established Myc inhibi-
tor, 10058-F4, that blocks c-Myc activity by disrupting the dimeriza-
tion of c-Myc with its obligate partner molecule, Max. As Myc-Max 
heterodimerization regulates c-Myc transcriptional activity, the 
inhibitor blocks c-Myc function.27,28 Indeed, 10058-F4 treatment 
suppressed the transcription of c-Myc target genes (Figure 3H). 
Collectively, these data imply that HFD alters c-Myc expression at 
the post-translational process, in MMECs, and the anomalous c-Myc 
activity influences the c-Myc-driven transcriptional regulation.
3.3 | High-fat diet stabilizes c-Myc
We investigated the mechanism underlying the HFD-mediated 
c-Myc stabilization in MMECs. Two phosphorylation events occur-
ring at serine 62 (S62) and threonine 58 (T58) are the key deter-
minants for c-Myc stability.29 S62 and T58 phosphorylation govern 
the ubiquitination-mediated proteasome degradation pathway of 
c-Myc turnover.30 c-Myc phosphorylated at S62 (pS62) has widely 
been reported to activate its function to stimulate transcription 
of target genes.31 Subsequently, c-Myc is phosphorylated at T58 
(pT58) by GSK-3β and directed to be recognized by E3 ligase stem 
cell factor.30,31
Notably, we detected an increased expression of c-Myc pS62 in 
HFD-MMECs with markedly upregulated c-Myc levels. (Figure 4A-
C). Although c-Myc pT58 expression was moderately changed be-
tween the 2 different diet groups (Figure 4A), the ratio of pS62 to 
pT58 c-Myc expression was substantially higher in HFD-MMECs 
(Figure 4D) compared to that in CD-MMECs. c-Myc stabilization 
primarily occurs through mitogenic activation of the Ras/Raf/MEK/
ERK axis.32 Next, we analyzed the activity of ERK, which is the ki-
nase responsible for c-Myc phosphorylation at S62. Indeed, we ob-
served enhanced ERK activity in HFD with concomitant induction 
of c-Myc (Figure 4E). Although the pT58 level was slightly altered 
in HFD, we noticed a remarkable reduction of GSK-3β expression 
between HFD-MMECs and CD-MMECs (Figure S3).
Furthermore, we determined the T1/2 of c-Myc in 3 different 
mouse pairs using CHX chase assay using IB. The HFD-MMECs 
showed a lower turnover rate of c-Myc compared to that of CD-
MMECs (Figure 4F,G) which is consistent with the altered pS62/
pT58. The IB band intensities obtained from the densitometric 
analysis are provided in Figure S4. Furthermore, on treating CD-
MMECs with a proteasomal inhibitor (MG-132), a significant c-Myc 
expression was detected in vitro (Figure S5), suggesting c-Myc 
undergoes proteasome degradation in MMECs. These findings 
support the notion that HFD promotes c-Myc stability due to en-
hanced ERK activity and augmented c-Myc phosphorylation at S62.
To further explore whether the activated ERK is responsible for 
HFD-driven upregulation of c-Myc, we used an inhibitor for ERK, 
U0126.33 The treatment antagonized the elevation of both pS62 
and c-Myc induced by HFD (Figure 4H). Moreover, U0126 exposure 
significantly antagonized the increased proliferation (Figure 4I) and 
colony formation of MMECs induced by HFD (Figure 4J,K).
To address whether the Trp53-null background is necessary for 
the c-Myc stabilization by HFD, we fed WT C57BL/6 mice with HFD 
or CD, as we did for Trp53−/− mice. We could not detect a dramatic 
modification in c-Myc activity in cultured MMECs derived from WT 
C57BL/6 mice fed either HFD or CD (data not shown). Moreover, WT 
MMECs failed to form colonies (data not shown). These findings sug-
gest several possibilities, eg the HFD effect on c-Myc stabilization is 
more evident in a Trp53-null background, or immortalization might be 
necessary for the presentation of c-Myc stabilization by HFD.
3.4 | High-fat diet stimulates MMECs to form 
colonies in a c-Myc-dependent manner
Next, we evaluated whether the increased colony-forming potential 
in HFD-MMECs (Figure 2B) is due to the enhanced c-Myc activity, 
by undertaking colony-forming assays in the presence of the Myc 
inhibitor 10058-F4. The 10058-F4 treatment significantly antago-
nized the elevated clonogenic activity in HFD-MMECs. These data 
suggest that c-Myc is responsible for the enhanced clonogenic activ-
ity in HFD (Figure 5).
3.5 | Oleic acid stabilizes c-Myc in MMECs
As fatty acid is one of the major constituents of HFD (Table S6), we 
postulated that the circulating FFA level might be elevated in mice 
with high fat intake. Moreover, HFD-derived serum FFA could be a 
F I G U R E  3   High-fat diet (HFD) induces altered expression of the c-Myc target genes and increases the c-Myc protein level. A, Principal 
component (PC) analyses of gene expression profile in HFD-mouse mammary epithelial cells (MMECs) (N = 3) and control diet (CD)-MMECs 
(N = 3). B, Heat map of clustering analysis of top 100 up- or downregulated genes in HFD-MMECs (N = 3) and CD-MMECs (N = 3) by 
weighted average differentiation. C, Enrichr analysis of Kyoto Encyclopedia of Genes and Genomes pathways significantly (adjusted P < .05) 
enriched in the top 100 upregulated genes in HFD-treated MMECs. D, Gene set enrichment of MYC signature (h.all.v7.0.symbols.gene.) 
in HFD-MMECs vs CD-MMECs. E, mRNA expression of indicated genes in CD-MMECs and HFD-MMECs. F, mRNA expression of c-Myc 
(N = 3). G, Immunoblotting of c-Myc protein in CD-MMECs and HFD-MMECs (N = 3). α-Tubulin was used as a loading control. H, mRNA 
expression of Klk8 gene in CD-MMECs and HFD-MMECs after treatment with Myc inhibitor 10058-F4 or DMSO for 24 h in the indicated 
concentrations (N = 3 for each group). Data are mean ± SE, *P < .05, **P < .01, ****P < .0001 (Student’s t test and 2-way ANOVA). FDR, false 
discovery rate; NES, net enrichment score; n.s., non-significant
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dietary factor that generates a tremendous influence on MMECs. As 
expected, FFA was found to be elevated in HFD-fed mice (Figure 6A).
To further investigate the effect of FFA, we treated MMECs with 
OA, which is a major fatty acid constituent of the HFD. We cultured 
CD-MMECs in serum-free media for 24 hours and then treated with 
30 µmol/L OA for an additional 48 hours. Immunoblotting analy-
sis revealed a dramatically enhanced expression of total c-Myc 
and c-Myc pS62 in OA-treated MMECs compared to their expres-
sion in control cells (Figure 6B). Moreover, we observed extended 
T1/2 of c-Myc in CD-MMECs when treated with OA (Figure 6C,D). 
Additionally, we found higher clonogenic and spherogenic activity in 
MMECs after treatment with OA (Figure 6E-H). These data indicate 
that serum fatty acid contributes to attenuated c-Myc degradation.
We addressed whether the activated ERK is directly responsi-
ble for the OA-induced c-Myc stability as we observed in HFD. We 
analyzed the effect of U0126 on OA-mediated induction of c-Myc 
and p-Myc (S62). Indeed, U0126 abrogated the enhanced c-Myc 
and p-Myc (S62) activity induced by OA treatment (Figure 6I). 
Consistently, U0126 suppressed the augmented colony formation 
induced by OA (Figure 6J,K).
To corroborate further that the OA promotes mitogenic sig-
nals to activate c-Myc, we treated MMECs with TAK-875, a GPR40 
agonist. G protein-coupled receptor 40 is recognized as a target 
of medium- to long-chain fatty acids, such as OA, to generate mi-
togenic signaling through the Gpr40-Mek-Erk axis.34 We found 
markedly elevated c-Myc expression in MMECs on TAK-875 ex-
posure in a time-dependent manner (Figure 6L). Additionally, we 
treated CD-MMECs with TAK-875 for 24 hours then with the ERK 
inhibitor U0126. This revealed that the pS62 expression and c-Myc 
protein expression increased following TAK-875 exposure was sig-
nificantly antagonized when the p-ERK expression was decreased 
(Figure 6M).
We used MCF10A, a nonmalignant immortalized human mam-
mary epithelial cell line, to investigate whether OA gives rise to a 
similar effect observed in human MMECs. Both OA and TAK-875 
augmented p-Myc (S62) and c-Myc levels (Figure S6) in MCF10A. As 
PA is one of the most abundant saturated fatty acids in serum, we 
attempted to reveal the influence of PA on c-Myc stability. We ob-
served a substantial increase of c-Myc and p-Myc (S62) in MMECs 
and MCF10A cells that were exposed to PA at lower concentra-
tions (25-50 µmol/L). However, PA at higher concentrations (100-
200 µmol/L) decreased c-Myc levels in MCF10A cells (Figure S7). 
Importantly, the PA-driven c-Myc induction was attained without 
p-ERK elevation (Figure S7). These findings suggest that PA might 
induce c-Myc at relatively low concentrations through an alter-
native pathway. Additionally, OA but not PA reduced GSK-3β in 
MMECs and MCF10A cells (Figure S8). Overall, our findings indi-
cate that HFD contributes to breast carcinogenesis in part by ex-
tending c-Myc stability through fatty acid-induced stimulation of 
mitogenic signaling.
F I G U R E  4   High-fat diet (HFD) stabilizes c-Myc. A, Immunoblotting (IB) of c-Myc phosphorylation at serine (S62) (pS62) and threonine 
(T58) (pT58) in control diet (CD)-mouse mammary epithelial cells (MMECs) and HFD-MMECs (N = 3). B, C, Quantitative analysis of 
expression of indicated proteins. D, Quantitative analysis of the pS62/pT58 using the IB data in (A). E, IB of indicated proteins in CD-MMECs 
and HFD-MMECs (N = 3). F, Cycloheximide (CHX) chase assay to determine the half-life of c-Myc in CD-MMECs and HFD-MMECs (N = 3). 
Cells were treated with 10 µg/mL CHX for the indicated time periods. G, Quantitative analysis of c-Myc half-life in CD-MMECs and HFD-
MMECs (N = 3). H, IB of indicated proteins in CD-MMECs and HFD-MMECs in the presence of DMSO or nmol/L ERK inhibitor U0126 for 
1 h. I, WST-1-based cell proliferation assay of CD-MMECs and HFD-MMECs treated with DMSO or nmol/L U0126. Medium was replenished 
every 24  h (N = 3 for each group). J, Colony formation assay of CD-MMECs and HFD-MMECs in the presence of DMSO or nmol/L U0126 
for 14 days. Cell culture medium was replenished every 72 h. K, Quantitative analysis of the colony area in (J) (N = 3 for each group). 
α-Tubulin was used as a loading control. ImageJ-NIH software was used to quantify IB band intensities. Data are the mean ± SE. *P < .05, 
**P < .01, ***P < .001, ****P < .0001 (Student’s t test and 2-way ANOVA) n.s., non-significant
F I G U R E  5   High-fat diet (HFD) stimulates mouse mammary epithelial cells (MMECs) to form colonies in a c-Myc-dependent manner. A, 
Colony formation assay of control diet (CD)-MMECs and HFD-MMECs treated with or 60 µmol/L c-Myc inhibitor 10058-F4 (N = 3). Cells 
(4 × 103) were seeded on day 0 onto 60-mm dishes and stained with crystal violet on day 14. B, Quantitative analysis of the average colony 
area in (A). Data are mean ± SE *P < .05, ****P < .0001 (2-way ANOVA)
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4  | DISCUSSION
Despite many studies reporting the crucial influence of HFD on 
mammary tumor initiation and promotion,7-9,11 the mechanistic in-
sight remains elusive. In the present study, we have determined that 
HFD intake during the peripubertal period has a remarkable impact 
on Trp53−/− MMECs through the stabilization of c-Myc oncoprotein.
c-Myc is known to be expressed at a higher level in the majority 
of human malignancies, including breast cancer.29,35,36 Many mouse 
models have revealed the critical role of c-Myc in initiating and pro-
moting a wide variety of tumors.29,37 Conventionally, c-Myc is known 
to be activated due to gene amplification, increased mRNA expres-
sion, or enhanced protein stability.29,35,38 c-Myc stability is regulated 
by phosphorylation events. Initially, c-Myc is phosphorylated at S62 
residue by ERK, which improves protein stability and facilitates c-Myc 
to activate transcription of the target genes.29,35,36 Subsequent phos-
phorylation at T58 residue by GSK-3β directs the protein to ubiquiti-
nation and proteasome-mediated degradation.30,39 In malignancies, 
c-Myc activity is increased due to its aberrant phosphorylation sta-
tus, which is attained by deregulation of mitogenic signals. Our study 
shows that HFD has the potential to augment c-Myc S62 phosphor-
ylation and to decrease GSK-3β activity, which enables c-Myc to gain 
extra stability. In normal cells, c-Myc expression is strictly regulated, 
and T1/2 of c-Myc is typically reported to be 20-30 minutes.
39,40 In the 
present study, T1/2 of c-Myc in CD-MMECs was found to be 18 min-
utes, whereas it was extended to 30 minutes in HFD-MMECs.
Malignantly transformed cells, including breast cancer cells, uti-
lize FFAs to mediate proliferation, invasion, and metastasis.41-45 Oleic 
acid is one of the long-chain fatty acids and a major fatty acid constit-
uent of the HFD. We found increased serum concentration of FFAs, 
including OA, in HFD-fed mice (Figure 6A). Serum fatty acid concen-
tration has already been recognized as a valuable clinical parameter 
in breast cancer patients.46,47 In particular, OA acts as an endogenous 
ligand for several types of receptors such as a class of GPRs known 
as FFARs to perform its diverse functions.48,49 Both FFAR1/GPR40 
and FFAR4/GPR120 are primarily activated by long-chain fatty acids 
such as OA.41,43,50 These receptors are predominantly expressed 
in breast cancer and noncancerous mammary epithelial cell lines 
and reported to mediate cell proliferation.41 Moreover, it has been 
proposed that OA induces ERK1/2 activity and subsequently stim-
ulates the proliferation of breast cancer cell lines such as MCF-7 and 
MDA-MB-231.43 Our present study together with the previous find-
ings in breast cancer cell lines indicate that serum OA could play a 
pivotal role in the prediction of breast cancers.
In conclusion, we here identified that HFD influences MMECs by 
stabilizing an oncoprotein, pointing to a novel mechanism underlying 
mammary carcinogenesis enhanced by dietary fat. We also propose 
that fat intake should be restricted during the peripubertal period to 
lower the breast cancer risk in later life. This study can be extended 
to accelerated stages of mammary gland development such as preg-
nancy and breastfeeding. Additionally, we suggest the possibility of 
using fatty acid receptor antagonists to preventor treat breast cancer.
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